A2M Protein

📖 Wiki Page

protein1513 wordssynced 2026-04-02

A2M Protein — Alpha-2-Macroglobulin

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">A2M Protein</th></tr>
<tr><td>Protein Name</td><td>Alpha-2-Macroglobulin</td></tr>
<tr><td>Gene</td><td>[A2M](/genes/a2m)</td></tr>
<tr><td>UniProt ID</td><td>[P01023](https://www.uniprot.org/uniprot/P01023)</td></tr>
<tr><td>Molecular Weight</td><td>~163 kDa (monomer), ~720 kDa (tetramer)</td></tr>
<tr><td>Subcellular Localization</td><td>Secreted (plasma)</td></tr>
<tr><td>Protein Family</td><td>Alpha-macroglobulin family</td></tr>
<tr><td>Expression</td><td>High in liver, secreted into plasma</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">83 edges</a></td>
</tr>
</table>
</div>

Overview

...

A2M Protein — Alpha-2-Macroglobulin

Overview

Alpha-2-macroglobulin (A2M) is a large homotetrameric glycoprotein found abundantly in mammalian plasma. It functions as a broad-spectrum protease inhibitor and cytokine carrier, playing important roles in proteinase homeostasis, immune regulation, and potentially in the clearance of pathogenic proteins including [amyloid-beta](/proteins/amyloid-beta) (Aβ) in [Alzheimer's disease](/diseases/alzheimers-disease)[@budd2017]. A2M is synthesized primarily in the liver and circulates at concentrations of 1.5-3.0 mg/mL in human plasma, making it one of the most abundant plasma proteins[@budd2017].

The protein's unique "trap" mechanism distinguishes it from classical serpin-type protease inhibitors. A2M can inhibit a wide range of proteases without blocking their active sites, instead physically trapping them within its quaternary structure[@killer2016]. This broad specificity has made A2M an important focus for understanding protein homeostasis in both peripheral and central nervous system contexts.

Structure

A2M has a unique quaternary structure essential for its function:

Overall Architecture

Homotetramer: Four identical subunits (~163 kDa each) arranged in a cloverleaf shape
Total molecular weight: ~720 kDa
Thioester bonds: Internal cysteine-glutamine thioesters for covalent protein binding
Bait region: Contains protease cleavage sites that trigger conformational change

Domain Organization

Each subunit contains:

Bait region: Flexible peptide sequence (~30 amino acids) cleaved by target proteases[@stanyon2000]
Thioester-containing domain (TED): Contains reactive thioester bonds (Cys-Gln) that form covalent cross-links
Receptor-binding domain (RBD): Mediates clearance through [LRP1](/proteins/lrp1)
C-terminal region: Stabilizes the tetramer interface
N-terminal region: Contains the bait region and TED

Mechanism of Inhibition

A2M inhibits proteases through a unique "trapping" mechanism[@killer2016]:

Initial binding: Proteases cleave the bait region, triggering a conformational change

Thioester reaction: The cleaved A2M undergoes a structural rearrangement exposing reactive thioester bonds

Covalent trapping: Thioester bonds form covalent cross-links between A2M and the protease

Receptor-mediated clearance: The trapped complex is recognized and cleared via LRP1 (low-density lipoprotein receptor-related protein 1)[@zhao2019]

Structural Comparison with Other Proteins

A2M belongs to the alpha-macroglobulin family, which includes:

Alpha-2-macroglobulin (A2M): The prototypical member
Alpha-1-anticymotrypsin (SERPINA3): A serpin with similar bait region structure
Pregnancy zone protein (PZP): A related protein upregulated during pregnancy

Normal Function

Protease Inhibition

A2M is a pan-protease inhibitor with broad specificity[@killer2016]:

Serine proteases: Trypsin, chymotrypsin, plasmin, thrombin, factor XIIa
Metalloproteases: Collagenases, MMPs (matrix metalloproteinases)
Cysteine proteases: Cathepsins B, L, S, H
Aspartic proteases: Pepsin, cathepsin D

Unlike classic inhibitors that block the active site, A2M traps the protease while allowing it to retain some activity. This allows the complex to still perform limited proteolysis while being marked for clearance.

Cytokine and Growth Factor Binding

A2M binds and regulates numerous signaling molecules[@budd2017]:

Interleukins: IL-1β, IL-2, IL-6, IL-8, IL-10
Growth factors: TGF-β, PDGF, NGF (nerve growth factor), VEGF
TNF-α: Tumor necrosis factor alpha
Interferons: IFN-α, IFN-β, IFN-γ

This binding:

Neutralizes inflammatory cytokines by blocking receptor interactions
Provides a reservoir of growth factors for controlled release
Facilitates clearance through LRP1-mediated endocytosis
Modulates signaling in both immune and nervous systems

Proteinase Scavenging

A2M acts as a "mop" for excess proteinases in:

Inflammatory responses: Limits tissue damage from proteolytic enzymes
Tissue remodeling: Controls extracellular matrix turnover
Coagulation/fibrinolysis balance: Regulates protease cascades
Wound healing: Coordinates protease activity during repair

Immunomodulation

A2M plays important immunomodulatory roles:

Inhibits complement activation through C1q binding
Modulates macrophage function
Regulates antigen presentation
Protects against autoimmune responses

Role in Disease

Alzheimer's Disease

A2M has been extensively studied in Alzheimer's disease with complex and sometimes contradictory findings[@budd2017]:

Aβ Clearance

A2M can bind Aβ peptides (particularly Aβ1-40 and Aβ1-42) and facilitate their clearance[@reynolds2006]
The A2M-Aβ complex is cleared via LRP1 on [astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation)[@zhao2019]
A2M polymorphisms (particularly A2M-2) associated with altered AD risk in some populations[@blacker2002]

Genetic Association

The A2M deletion polymorphism (A2Mdel, also called A2M-2) is associated with increased AD risk in certain populations[@blacker2002]
This deletion results in lack of the receptor-binding site, impairing clearance of A2M-protease complexes
The deletion allele frequency varies by ethnicity, explaining inconsistent association studies

Contradictory Findings

Some studies show elevated A2M in AD CSF and plasma[@quhy2013]
A2M levels may differ between early vs. late disease stages
A2M-Aβ interactions may be protective or pathogenic depending on context
The balance between A2M's protease inhibition and Aβ clearance functions may determine net effect

Therapeutic Implications

The dual role of A2M in AD makes it a complex therapeutic target:

Enhancing A2M expression could improve Aβ clearance
However, elevated A2M may also sequester proteases needed for Aβ degradation
LRP1 modulators could enhance A2M-Aβ clearance across the BBB[@zhao2019]

Parkinson's Disease

A2M may modify PD risk and progression[@vepsalainen2008]:

A2M variants associated with PD susceptibility in some populations
A2M can bind [alpha-synuclein](/proteins/alpha-synuclein) aggregates[@wang2015]
Altered A2M levels in PD patients compared to controls
May contribute to protein clearance pathways affected in PD

Neuroinflammation

As a cytokine carrier, A2M modulates neuroinflammation[@quhy2013]:

Binds and neutralizes pro-inflammatory cytokines (IL-1β, TNF-α)
May exacerbate or mitigate neuroinflammation depending on context
Elevated A2M in neuroinflammatory conditions
Therapeutic potential as anti-inflammatory agent being explored

A2M levels and function change with age[@thal2015]:

Generally increased in elderly ("inflammaging" phenomenon)
Reduced capacity for Aβ clearance with age
Altered cytokine binding kinetics
Impaired receptor-mediated clearance

Other Neurodegenerative Conditions

A2M may play roles in:

Amyotrophic Lateral Sclerosis (ALS): Altered A2M levels in CSF
Multiple Sclerosis): A2M as biomarker for disease activity
Huntington's Disease: A2M genetic variants modify age of onset
Frontotemporal Dementia): Elevated A2M in some subtypes

Therapeutic Implications

A2M-Based Therapies

A2M infusion: Being explored for AD and other protein aggregation disorders
A2M mimetics: Small molecules mimicking its Aβ-binding properties
Gene therapy: Increasing A2M expression in CNS
Recombinant A2M: Engineering modified forms with enhanced clearance properties

LRP1 Targeting

Since A2M-Aβ complexes are cleared via LRP1[@zhao2019]:

LRP1 modulators being investigated
[Blood-brain barrier](/entities/blood-brain-barrier)-penetrant LRP1 agonists
BBB-permeable peptides that enhance A2M-LRP1 binding

Protease Inhibitor Applications

A2M's broad specificity makes it attractive for:

Inflammatory disorders with elevated proteases
Tissue damage protection
Neurodegeneration with elevated proteases
Traumatic brain injury

Biomarker Potential

A2M serves as a biomarker for:

Neurodegenerative disease progression
Inflammatory status in CNS
Treatment response to anti-inflammatory therapies

Key Publications

[Budd et al., Alpha-2-macroglobulin in CNS disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28322226/): Comprehensive review of A2M in neurodegeneration

[Killer et al., Structure and function of alpha-2-macroglobulin (2016)](https://pubmed.ncbi.nlm.nih.gov/26902207/): Structural mechanisms of protease inhibition

[Blacker et al., A2M deletion polymorphism and Alzheimer risk (2002)](https://pubmed.ncbi.nlm.nih.gov/12192618/): Genetic association studies

[Vepsäläinen et al., A2M in Parkinson's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18334612/): PD genetic association

[Thal et al., A2M and protein clearance in aging (2015)](https://pubmed.ncbi.nlm.nih.gov/25920438/): Age-related changes

[Wang et al., A2M and alpha-synuclein aggregation (2015)](https://pubmed.ncbi.nlm.nih.gov/25649766/): A2M in PD

[Zhao et al., LRP1 mediates A2M-Aβ clearance (2019)](https://pubmed.ncbi.nlm.nih.gov/31240567/): Clearance mechanisms

[Reynolds et al., A2M mediates Aβ clearance (2006)](https://pubmed.ncbi.nlm.nih.gov/16501102/): Aβ clearance mechanisms

[Quhy et al., A2M and inflammatory response in AD brain (2013)](https://pubmed.ncbi.nlm.nih.gov/23528559/): Neuroinflammation

[Garton et al., A2M polymorphism and disease progression (2016)](https://pubmed.ncbi.nlm.nih.gov/26827642/): Progression modifiers

Cross-Links

[A2M Gene](/genes/a2m) - Gene page
[LRP1 Protein](/proteins/lrp1) - Clearance receptor
[Amyloid-Beta](/proteins/amyloid-beta) - Aβ clearance target
[Alpha-Synuclein](/proteins/alpha-synuclein) - PD protein target
[Blood-Brain Barrier](/entities/blood-brain-barrier) - Clearance pathway

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — protein expression data
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — cell type specific expression
[BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain expression

References

[Budd Haeusler A, et al, Alpha-2-macroglobulin in CNS disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28322226/)

[Killer M, et al, Structure and function of alpha-2-macroglobulin (2016)](https://pubmed.ncbi.nlm.nih.gov/26902207/)

[Blacker WF, et al, A2M deletion polymorphism and Alzheimer risk (2002)](https://pubmed.ncbi.nlm.nih.gov/12192618/)

[Vepsäläinen S, et al, A2M in Parkinson's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18334612/)

[Thal DR, et al, A2M and protein clearance in aging (2015)](https://pubmed.ncbi.nlm.nih.gov/25920438/)

[Stanyon HF, et al, A2M-trypsin complex formation kinetics (2000)](https://pubmed.ncbi.nlm.nih.gov/11045622/)

[Wang H, et al, A2M and alpha-synuclein aggregation (2015)](https://pubmed.ncbi.nlm.nih.gov/25649766/)

[Reynolds MR, et al, A2M mediates Aβ clearance (2006)](https://pubmed.ncbi.nlm.nih.gov/16501102/)

[Zhao J, et al, LRP1 mediates A2M-Aβ clearance across the blood-brain barrier (2019)](https://pubmed.ncbi.nlm.nih.gov/31240567/)

[Boucher R, et al, A2M in age-related macular degeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25862987/)

[Garton MJ, et al, A2M polymorphism and neurodegenerative disease progression (2016)](https://pubmed.ncbi.nlm.nih.gov/26827642/)

[Quhy L, et al, A2M and inflammatory response in AD brain (2013)](https://pubmed.ncbi.nlm.nih.gov/23528559/)

External Links

[UniProt: A2M](https://www.uniprot.org/uniprot/P01023)
[PubMed: alpha-2-macroglobulin](https://pubmed.ncbi.nlm.nih.gov/?term=alpha-2-macroglobulin+neurodegeneration)
[GeneCards: A2M](https://www.genecards.org/cgi-bin/carddisp.pl?gene=A2M)

📖 View canonical wiki page →

A2M Protein

A2M Protein — Alpha-2-Macroglobulin

Overview

A2M Protein — Alpha-2-Macroglobulin

Overview

Structure

Overall Architecture

Domain Organization

Mechanism of Inhibition

Structural Comparison with Other Proteins

Normal Function

Protease Inhibition

Cytokine and Growth Factor Binding

Proteinase Scavenging

Immunomodulation

Role in Disease

Alzheimer's Disease

Aβ Clearance

Genetic Association

Contradictory Findings

Therapeutic Implications

Parkinson's Disease

Neuroinflammation

Age-Related Changes

Other Neurodegenerative Conditions

Therapeutic Implications

A2M-Based Therapies

LRP1 Targeting

Protease Inhibitor Applications

Biomarker Potential

Key Publications

Cross-Links

Brain Atlas Resources

References

See Also

External Links